Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011 (2011), Article ID 947858, 10 pages
Review Article

PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors

Department of Emergency and Organ Transplantation, Section of Internal Medicine, Allergology and Clinical Immunology, University of Bari Medical School, 70124 Bari, Italy

Received 31 May 2011; Revised 18 August 2011; Accepted 21 August 2011

Academic Editor: Bernhard Fleischer

Copyright © 2011 Francesco Dituri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The immunological surveillance of tumors relies on a specific recognition of cancer cells and their associate antigens by leucocytes of innate and adaptive immune responses. However, a dysregulated cytokine release can lead to, or be associated with, a failure in cell-cell recognition, thus, allowing cancer cells to evade the killing system. The phosphatidylinositol 3-kinase (PI3K) pathway regulates multiple cellular processes which underlie immune responses against pathogens or malignant cells. Conversely, there is accumulating evidence that the PI3K pathway is involved in the development of several malignant traits of cancer cells as well as their escape from immunity. Herein, we review the counteracting roles of PI3K not only in antitumor immune response but also in the mechanisms that cancer cells use to avoid leukocyte attack. In addition, we discuss, from antitumor immunological point of view, the potential benefits and disadvantages arising from use of anticancer pharmacological agents targeting the PI3K pathway.